Effects of Long-Term Treatment With Nasally Inhaled Triamcinolone Acetonide in Children With Allergic Rhinitis

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Study Classification

OBSERVATIONAL

Study Completion Date

2007-06-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Seasonal/perennial allergic rhinitis (SAR/PAR) is a common childhood illness. One of the leading therapies for the treatment of SAR/PAR is intranasally inhaled corticosteroids (ICS). One of the major long-term safety concerns is whether ICS interferes with normal growth in allergic rhinitis children. Recent evidence suggests that nasal ICS may cause decreased growth. However, the effect of nasal ICS on long-term growth and the attainment of final adult height is unknown. Another potential systemic adverse effect of ICS use is suppression of the hypothalamic-pituitary-adrenal axis function. The primary hypothesis of this study is that triamcinolone acetonide aqueous nasal spray (TAA) will have no effect on measured adult height in relation to target adult height in children with allergic rhinitis.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Allergic Rhinitis Allergy Growth

Keywords

Explore important study keywords that can help with search, categorization, and topic discovery.

Allergic Rhinitis Allergy Growth

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Male/Female aged 6-13 years of age
* Diagnosis of SAR/PAR, with symptoms within the past 3 months
* Positive skin test to inhalant allergen with negative saline control
* No previous use of intranasal inhaled, oral, IV or topical steroid use within past 6 months.
* If the subject has asthma, only mild intermittent (per NAPP) guidelines treated with PRN bronchodilator

Exclusion Criteria

* screening height outside the 5th and 95th percentiles
* History of abnormal growth
* Any other chronic condition beside allergic rhinitis or mild intermittent asthma
* Subject who has insufficient allergic rhinitis symptoms to require daily therapy during the trial.
* Subject with a known hypersensitivity to any active ingredients or excipents in the study medications
* Subject with nasal candidiasis, acute or chronic sinusitis, significant nasal polyposis (impairs nasal breathing), or other gross anatomical deformity of the nose sufficient to impair nasal breathing (e.g., deviated septum)
* Subjects with a history of substance abuse, mental illness or retardation
* Subjects with a history or presence of glaucoma or posterior subcapsular cataract
* Subjects with nocturnal enuresis.
* Use of Theophylline, Intal/Tilade or leukotriene modifiers.

Minimum Eligible Age

6 Years

Maximum Eligible Age

13 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

David Skoner, MD

Role: PRINCIPAL_INVESTIGATOR

West Penn Allegheny Health System

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Allegheny General Hospital

Pittsburgh, Pennsylvania, United States

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

RC - 3421

Identifier Type: -

Identifier Source: secondary_id

IST Nasacort AQ NAS.US1.631